Invention Publication
- Patent Title: INHIBITORS OF MLH1 AND/OR PMS2 FOR CANCER TREATMENT
-
Application No.: US17925493Application Date: 2020-06-01
-
Publication No.: US20230183197A1Publication Date: 2023-06-15
- Inventor: Julian Blagg , Jon Roffey , Martin Drysdale , Paul Winship , David Clark
- Applicant: NeoPhore Limited
- Applicant Address: GB Cheshire
- Assignee: NeoPhore Limited
- Current Assignee: NeoPhore Limited
- Current Assignee Address: GB Cheshire
- Priority: GB 08201.2 2020.06.01
- International Application: PCT/GB2021/051349 2020.06.01
- Date entered country: 2022-11-15
- Main IPC: C07D295/16
- IPC: C07D295/16 ; C07D239/26 ; C07D209/44 ; C07D207/12 ; C07D211/42 ; C07D213/16 ; C07D471/04 ; C07D231/12 ; C07D249/04 ; C07D401/12 ; C07D217/04 ; C07D217/16 ; C07D265/36 ; C07D209/08 ; C07D215/08 ; C07D405/12 ; C07D401/04 ; C07D403/12 ; C07D403/04 ; A61K45/06
Abstract:
The present invention relates to compounds of Formula (I) that target the MLH1 and/or PMS2 proteins that are components of the DNA Mismatch Repair (MMR) process:
wherein R1, R2, R3, R4, R6 and R10 are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which MLH1 and/or PMS2 activity is implicated.
wherein R1, R2, R3, R4, R6 and R10 are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which MLH1 and/or PMS2 activity is implicated.
Information query
